Management of obesity: pharmacological approach
AbstractToday, weight gain has a number of negative consequences, including a significant increase in the risk of diabetes mellitus. This article highlights the evidence on the effects of drug therapy with sibutramine, a neurotransmitter reuptake inhibitor, and its effects in combination with metformin in patients with obesity.
Keywords:obesity; diabetes mellitus; drug therapy; sibutramine
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Ametov A.S., Vovk P.S. Management of obesity: pharmacological approach. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (4): 89–94. DOI: https://doi.org/10.33029/2304-9529-2022-11-4-89-94 (in Russian)
References
1. World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
2. Ametov A.S. The Obesity. Modern view on pathogenesis and therapy: Textbook. Moscow: GEOTAR-Media, 2019; (1): 384 p. (in Russian)
3. Peterkova V.A., Bezlepkina O.B., Bolotova N.V., Bogova E.A., et al. Clinical guidelines “Obesity in children”. Problemi endocrinologii [Problems of Endocrinology]. 2021; 67 (5): 67–83. DOI: https://doi.org/10.14341/probl12802 (in Russian)
4. Tishkovskiy S.V., Nikonova L.V., Doroshkevich I.P. Modern approaches to treatment of obesity. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta [Journal of the Grodno State Medical University]. 2015: (2): 134–9. URL: https://cyberleninka.ru/article/n/sovremennye-podhody-k-lecheniyu-ozhireniya (in Russian)
5. Taganov A.V., Tikhomirov T.A., Rozhdestvenskaya O.A., Zaslavsky D.V., et al. Obesity as a factor contributing to pathogenesis of skin diseases. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (4): 52–61. DOI: https://doi.org/10.33029/2304-9529-2021-10-4-52-61 (in Russian)
6. Misharova A.P., Ametov A.S. Adipose tissue as a plastic organ to management obesity and diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (2): 64–70. DOI: https://doi.org/10.33029/2304-9529-2022-11-2-64-70 (in Russian)
7. Bray G.A., Heisel W.E., Afshin A., et al. The Science of Obesity Management: An Endocrine Society Scientific Statement // Endocr Rev. 2018; 39 (2): 79–132.
8. Zembic A., Eckel N., Stefan N., Baudry J., Schulze M.B. An empirically derived definition of metabolically healthy obesity based on risk of cardiovascular and total mortality. JAMA Netw Open. 2021; 4 (5):e218505. DOI: https://doi.org/10.1001/jamanetworkopen.2021.8505
9. Romantsova T.I., Ostrovskaya E.V. Metabolically healthy obesity: definitions, protective factors, and clinical significance. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2015; (1): 75–86. (in Russian)
10. Pyanykh O.P., Gusenbekova D.G., Ametov A.S. Advantages of long-term management the metabolic health in patients with obesity and early disorders of carbohydrate metabolism. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (2): 40–8. DOI: https://doi.org/10.33029/2304-9529-2020-9-2-40-48 (in Russian)
11. Ametov A.S., Pyanykh O.P., Nevolnikova A.O. Modern opportunities of metabolic health management in patients with obesity and carbohydrate metabolism disorders. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (1): 17–26. DOI: https://doi.org/10.33029/2304-9529-2020-9-1-17-26 (in Russian)
12. Sjöström L., Rissanen A., Andersen T., et al.; European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352 (9123): 167–72. DOI: https://doi.org/10.1016/s0140-6736(97)11509-4
13. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27 (1): 155–61. DOI: https://doi.org/10.2337/diacare.27.1.155
14. Antsiferov M.B., Markova T.N. State-of-the-art drug therapies of obesity. Doctor.Ru. 2021; 20 (2): 45–50. DOI: https://doi.org/10.31550/1727-2378-2021-20-2-45-50 (in Russian)
15. Chukhrova M.G. Eating disorders and psychological disorders in women with excessive body weight. Psychosomatic medicine: materials of the 1st International Congress, 8–9 June 2006, St. Petersburg. St. Petersburg: Medlay-Media Publ., 2006: 244 p. (in Russian)
16. Moncrieff J., Cooper R.E., Stockmann T., et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022. DOI: https://doi.org/10.1038/s41380-022-01661-0
17. Leonova E.N. Socio-psychological types of eating behavior. Vestnik Udmurtskogo universiteta. Seriya “Filosofiya. Psikhologiya. Pedagogika” [Bulletin of Udmurt University. Series: Philosophy. Psychology. Pedagogy]. 2017; 27 (2): 174–81. (in Russian)
18. Salmina-Khvostova O.I. Eating disorder at obesity (epidemiological, clinicaldynamic, preventive, rehabilitation aspects): Abstract of Diss. Tomsk, 2008: 42 p. (in Russian)
19. Matveev G.А., Babenko A.Yu. Efficacy of sibutramine in different types of eating behavior in obese patients. Medical Council [Meditsinskiy Sovet]. 2022; 16 (10): 140–7. DOI: https://doi.org/10.21518/2079-701X-2022-16-10-140-147 (in Russian)
20. Matveev G.A., Golikova T.I., Vasileva A.A., Vasilieva E.V., et al. Comparison of the effects of liraglutide and sibutramine in obese patients. Ozhirenie i metabolism [Obesity and Metabolism]. 2021; 18 (2): 218–28. DOI: https://doi.org/10.14341/omet12498 (in Russian)
21. Galieva M.O., Ershova E.V., Komshilova K.A. Sibutramine: myths and realities. Ozhirenie i metabolism [Obesity and Metabolism]. 2014; 11 (4): 12–7. (in Russian)
22. Porter J.A., Raebel M.A., Conner D.A., et al. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care. 2004; 10 (6): 369–76.
23. Hayes J.F., Bhaskaran K., Batterham R., Smeeth L., Douglas I. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. Int J Obes (Lond). 2015; 39 (9): 1359–64. DOI: https://doi.org/10.1038/ijo.2015.86
24. Demidova T.Yu., Izmailova M.Ya., Ushakova S.E., Zaslavskaya K.Ya., et al. Evaluation of weight reduction efficacy and safety of sibutramin-containing drugs in patients with alimentary obesity. Farmatsiya i farmakologiya [Pharmacy & Pharmacology]. 2022; 10 (3): 289–304. DOI: https://doi.org/10.19163/2307-9266-2022-10-3-289-304 (in Russian)